Teva Canada Limited v. Sanofi-Aventis Canada Inc. , 2014 FCA 67 (Ramipril*)
Justice Sharlow; Justice Dawson; Justice Mainville - 2014-03-14
Read full decision. Automatically generated summary:
These reasons concern an appeal (docket A-147-12) brought by Teva Canada Limited (“Teva”) and a cross-appeal brought by Sanofi-Aventis Canada Inc. and Sanofi-Aventis Deutschland GmbH (“Sanofi”) from a judgment of Snider J. of the Federal Court (the “Trial Judge”) dated May 11, 2012 (the “Liability Judgment”) issued for reasons cited as 2012 FC 552 and publicly released on May 23, 2012. The Liability Judgment ordered Sanofi to compensate Teva pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (“NOC Regulations”) for its net lost profits in respect of 2.5, 5 and 10 mg capsules of Teva’s generic version of ramipril during the period commencing December 13, 2005 and ending April 27, 2007.
Decision relates to:
- A-147-12 - TEVA CANADA LIMITED v. SANOFI-AVENTIS CANADA INC. ET AL which is an appeal from 2012 FC 552 in T-1161-07